Restructuring proteomics through verification.
Proteomics technologies have revolutionized cell biology and biochemistry by providing powerful new tools to characterize complex proteomes, multiprotein complexes and post-translational modifications. Although proteomics technologies could address important problems in clinical and translational cancer research, attempts to use proteomics approaches to discover cancer biomarkers in biofluids and tissues have been largely unsuccessful and have given rise to considerable skepticism. The National Cancer Institute has taken a leading role in facilitating the translation of proteomics from research to clinical application, through its Clinical Proteomic Technologies for Cancer. This article highlights the building of a more reliable and efficient protein biomarker development pipeline that incorporates three steps: discovery, verification and qualification. In addition, we discuss the merits of multiple reaction monitoring mass spectrometry, a multiplex targeted proteomics platform, which has emerged as a potentially promising, high-throughput protein biomarker measurements technology for preclinical 'verification'.
Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, NIH, 31 Center Drive, MS 2590, Bethesda, MD 20892, USA.
Emily
E
Boja
Robert
R
Rivers
Christopher
C
Kinsinger
Mehdi
M
Mesri
Tara
T
Hiltke
Amir
A
Rahbar
Henry
H
Rodriguez
D015415:Biomarkers / Q000032:analysis*; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods / Q000639:trends; D054547:National Cancer Institute (U.S.); D040901:Proteomics / Q000379:methods* / Q000592:standards* / Q000639:trends; D015203:Reproducibility of Results; D014481:United States; D014486:United States Food and Drug Administration
D015415:Biomarkers